[{"id":"239cfbfd-4502-4f5e-a5da-4b96cfe72590","acronym":"","url":"https://clinicaltrials.gov/study/NCT07498400","created_at":"2026-04-04T01:40:42.252Z","updated_at":"2026-04-04T01:40:42.252Z","phase":"","brief_title":"Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer","source_id_and_acronym":"NCT07498400","lead_sponsor":"Xijing Hospital","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2026-03-27"},{"id":"15523e72-2092-4615-84e9-c8dac7362a0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07484087","created_at":"2026-03-28T01:36:33.328Z","updated_at":"2026-03-28T01:36:33.328Z","phase":"","brief_title":"Ablation Compare With Surgery for Early Breast Cancer","source_id_and_acronym":"NCT07484087","lead_sponsor":"Peking University People's Hospital","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + AR positive + ER positive"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2026-03-19"},{"id":"09a2d6c3-0189-486e-8048-e063641e4790","acronym":"","url":"https://clinicaltrials.gov/study/NCT07480694","created_at":"2026-03-28T01:39:28.152Z","updated_at":"2026-03-28T01:39:28.152Z","phase":"","brief_title":"Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC","source_id_and_acronym":"NCT07480694","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2026-03-18"},{"id":"855e0615-efe8-444c-a20c-79fd80778922","acronym":"","url":"https://clinicaltrials.gov/study/NCT07475923","created_at":"2026-03-28T01:38:45.775Z","updated_at":"2026-03-28T01:38:45.775Z","phase":"","brief_title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","source_id_and_acronym":"NCT07475923","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/26/2026","start_date":" 08/26/2026","primary_txt":" Primary completion: 12/31/2031","primary_completion_date":" 12/31/2031","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2026-03-17"},{"id":"88f3eaef-14f2-44c3-90f7-c4ebafee84e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474064","created_at":"2026-03-28T01:40:03.816Z","updated_at":"2026-03-28T01:40:03.816Z","phase":"Phase 2","brief_title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","source_id_and_acronym":"NCT07474064","lead_sponsor":"chenxu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/26/2026","start_date":" 03/26/2026","primary_txt":" Primary completion: 03/31/2031","primary_completion_date":" 03/31/2031","study_txt":" Completion: 03/31/2035","study_completion_date":" 03/31/2035","last_update_posted":"2026-03-17"},{"id":"b06c4a15-488d-4c26-b536-d32ff1360c20","acronym":"EINSTEIN-TNBC","url":"https://clinicaltrials.gov/study/NCT07478705","created_at":"2026-03-28T01:41:18.017Z","updated_at":"2026-03-28T01:41:18.017Z","phase":"","brief_title":"Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging","source_id_and_acronym":"NCT07478705 - EINSTEIN-TNBC","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2026","start_date":" 05/01/2026","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2026-03-17"},{"id":"778d6e97-aaea-4385-b9ac-14c267296d2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474324","created_at":"2026-03-28T01:42:37.705Z","updated_at":"2026-03-28T01:42:37.705Z","phase":"Phase 2","brief_title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","source_id_and_acronym":"NCT07474324","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2026-03-16"},{"id":"85d00d86-52dd-4bea-8f18-fb91850677e6","acronym":"STEPS-BC","url":"https://clinicaltrials.gov/study/NCT07474090","created_at":"2026-03-28T01:42:32.996Z","updated_at":"2026-03-28T01:42:32.996Z","phase":"","brief_title":"Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial","source_id_and_acronym":"NCT07474090 - STEPS-BC","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/05/2026","start_date":" 07/05/2026","primary_txt":" Primary completion: 09/01/2029","primary_completion_date":" 09/01/2029","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2026-03-16"},{"id":"503fb49c-7f9c-44d3-9d06-e13901c0cc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471815","created_at":"2026-03-28T01:43:58.232Z","updated_at":"2026-03-28T01:43:58.232Z","phase":"Phase 2","brief_title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","source_id_and_acronym":"NCT07471815","lead_sponsor":"Harbin Medical University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/04/2026","start_date":" 03/04/2026","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2026-03-13"},{"id":"5d9e65c6-b900-41df-834e-6e18a16cdf9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470203","created_at":"2026-03-28T01:44:18.552Z","updated_at":"2026-03-28T01:44:18.552Z","phase":"","brief_title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","source_id_and_acronym":"NCT07470203","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/31/2026","start_date":" 03/31/2026","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"dddae553-9ce4-4728-9047-032010347ec6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471776","created_at":"2026-03-28T01:44:37.396Z","updated_at":"2026-03-28T01:44:37.396Z","phase":"Phase 2","brief_title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","source_id_and_acronym":"NCT07471776","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/11/2026","start_date":" 03/11/2026","primary_txt":" Primary completion: 03/11/2028","primary_completion_date":" 03/11/2028","study_txt":" Completion: 03/11/2029","study_completion_date":" 03/11/2029","last_update_posted":"2026-03-13"},{"id":"3aba5b38-3db1-4e50-b966-dbbd60ad2e6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863818","created_at":"2025-09-07T01:52:13.355Z","updated_at":"2025-09-07T01:52:13.355Z","phase":"","brief_title":"Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs","source_id_and_acronym":"NCT06863818","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" EGFR • HER-2 • MET • ERBB3 • NRG1 • ERBB4","pipe":"","alterations":" ","tags":["EGFR • HER-2 • MET • ERBB3 • NRG1 • ERBB4"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/10/2022","start_date":" 10/10/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-03-07"},{"id":"08b2bc8f-c536-4ab4-95bd-8afe3b23bcd7","acronym":"NRG-GY026","url":"https://clinicaltrials.gov/study/NCT05256225","created_at":"2022-02-25T17:52:52.661Z","updated_at":"2025-02-25T12:28:40.900Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer","source_id_and_acronym":"NCT05256225 - NRG-GY026","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 525","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-24"},{"id":"2155cc55-44be-403d-a3c7-183b3abe530b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638295","created_at":"2022-12-06T16:58:31.646Z","updated_at":"2025-02-25T12:29:13.134Z","phase":"Phase 2","brief_title":"Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05638295","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS","pipe":"","alterations":" ","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"356e037f-a448-4ff1-b399-8d43d9152a11","acronym":"","url":"https://clinicaltrials.gov/study/NCT05946668","created_at":"2023-07-14T18:09:09.966Z","updated_at":"2025-02-25T12:38:41.091Z","phase":"","brief_title":"Evaluation of Vaginal Microbiome As a Biomarker for the Improvement of Vaginal Health in Women with Breast Cancer, ARISE Study","source_id_and_acronym":"NCT05946668","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2025-02-24"},{"id":"53a3393c-70b7-4bcc-a8e3-5120097c6768","acronym":"OVELIA","url":"https://clinicaltrials.gov/study/NCT04906395","created_at":"2021-05-28T13:52:36.773Z","updated_at":"2025-02-25T12:28:09.357Z","phase":"Phase 3","brief_title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","source_id_and_acronym":"NCT04906395 - OVELIA","lead_sponsor":"Tolmar Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-24"},{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"74157a34-d6de-4ba9-9962-025f2effcf7f","acronym":"ALPHABET","url":"https://clinicaltrials.gov/study/NCT05063786","created_at":"2021-10-01T11:54:26.039Z","updated_at":"2025-02-25T12:37:59.796Z","phase":"Phase 3","brief_title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","source_id_and_acronym":"NCT05063786 - ALPHABET","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-24"},{"id":"7b820269-141f-4024-866b-63f1d5de0853","acronym":"S2206","url":"https://clinicaltrials.gov/study/NCT06058377","created_at":"2023-09-28T14:10:22.699Z","updated_at":"2025-02-25T12:29:51.382Z","phase":"Phase 3","brief_title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","source_id_and_acronym":"NCT06058377 - S2206","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 3680","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-24"},{"id":"cc900cf1-cbd5-4b72-929f-5a7f0c8da6dd","acronym":"KEYNOTE-797","url":"https://clinicaltrials.gov/study/NCT04042701","created_at":"2021-01-18T19:49:50.989Z","updated_at":"2025-02-25T12:37:23.766Z","phase":"Phase 1","brief_title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04042701 - KEYNOTE-797","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"e892208a-36f9-4d6f-a38c-e7cd64d31bd9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03659136","created_at":"2021-01-18T17:57:27.537Z","updated_at":"2025-02-25T12:26:58.565Z","phase":"Phase 2","brief_title":"The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread","source_id_and_acronym":"NCT03659136","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • exemestane • xentuzumab (BI-836845)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 11/28/2018","start_date":" 11/28/2018","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 05/11/2022","study_completion_date":" 05/11/2022","last_update_posted":"2025-02-24"},{"id":"fe52e481-e906-4f7f-a53f-550a7128a15c","acronym":"EVANGELINE","url":"https://clinicaltrials.gov/study/NCT05607004","created_at":"2022-11-07T13:56:21.386Z","updated_at":"2025-02-25T12:38:26.751Z","phase":"Phase 2","brief_title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","source_id_and_acronym":"NCT05607004 - EVANGELINE","lead_sponsor":"Atossa Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 02/14/2023","start_date":" 02/14/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-24"},{"id":"06f9902f-3398-49ea-bdd4-ce2518db4d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886531","created_at":"2021-05-14T12:52:33.790Z","updated_at":"2025-02-25T13:49:09.000Z","phase":"Phase 2","brief_title":"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","source_id_and_acronym":"NCT04886531","lead_sponsor":"Ruth O'Regan","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-21"}]